Pieris Pharmaceuticals Inc. [PIRS] moved up 12.25: Why It’s Important

Related

Pieris Pharmaceuticals Inc. [NASDAQ: PIRS] gained 12.25% on the last trading session, reaching $3.94 price per share at the time. The company report on November 11, 2021 that Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences:


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Pieris Pharmaceuticals Inc. represents 67.73 million in outstanding shares, while the company has a total market value of $273.12 million with the latest information. PIRS stock price has been found in the range of $3.48 to $3.96.

If compared to the average trading volume of 886.38K shares, PIRS reached a trading volume of 2081418 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Pieris Pharmaceuticals Inc. [PIRS]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PIRS shares is $8.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PIRS stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Robert W. Baird have made an estimate for Pieris Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 13, 2020. The new note on the price target was released on July 30, 2019, representing the official price target for Pieris Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $5, while Robert W. Baird analysts kept a Outperform rating on PIRS stock.

The Average True Range (ATR) for Pieris Pharmaceuticals Inc. is set at 0.26, with the Price to Sales ratio for PIRS stock in the period of the last 12 months amounting to 10.97. The Price to Book ratio for the last quarter was 4.93.

Trading performance analysis for PIRS stock

Pieris Pharmaceuticals Inc. [PIRS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.61. With this latest performance, PIRS shares gained by 19.39% in over the last four-week period, additionally plugging by 2.07% over the last 6 months – not to mention a rise of 48.68% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PIRS stock in for the last two-week period is set at 59.85, with the RSI for the last a single of trading hit 66.78, and the three-weeks RSI is set at 55.08 for Pieris Pharmaceuticals Inc. [PIRS]. The present Moving Average for the last 50 days of trading for this stock 3.81, while it was recorded at 3.58 for the last single week of trading, and 3.65 for the last 200 days.

Pieris Pharmaceuticals Inc. [PIRS]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Pieris Pharmaceuticals Inc. [PIRS] shares currently have an operating margin of -115.68. Pieris Pharmaceuticals Inc.’s Net Margin is presently recorded at -126.97.

Return on Total Capital for PIRS is now -58.71, given the latest momentum, and Return on Invested Capital for the company is -65.43. Return on Equity for this stock declined to -90.39, with Return on Assets sitting at -30.26. When it comes to the capital structure of this company, Pieris Pharmaceuticals Inc. [PIRS] has a Total Debt to Total Equity ratio set at 54.67. Additionally, PIRS Total Debt to Total Capital is recorded at 35.35, with Total Debt to Total Assets ending up at 16.15. Long-Term Debt to Equity for the company is recorded at 51.35, with the Long-Term Debt to Total Capital now at 33.20.

Reflecting on the efficiency of the workforce at the company, Pieris Pharmaceuticals Inc. [PIRS] managed to generate an average of -$302,683 per employee. Receivables Turnover for the company is 6.91 with a Total Asset Turnover recorded at a value of 0.24.Pieris Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.80 and a Current Ratio set at 2.80.

>> 7 Top Picks for the Post-Pandemic Economy <<

An analysis of insider ownership at Pieris Pharmaceuticals Inc. [PIRS]

There are presently around $112 million, or 51.50% of PIRS stock, in the hands of institutional investors. The top three institutional holders of PIRS stocks are: BVF INC/IL with ownership of 5,328,239, which is approximately 0% of the company’s market cap and around 11.01% of the total institutional ownership; AQUILO CAPITAL MANAGEMENT, LLC, holding 3,196,527 shares of the stock with an approximate value of $11.22 million in PIRS stocks shares; and CITADEL ADVISORS LLC, currently with $8.11 million in PIRS stock with ownership of nearly 10.836% of the company’s market capitalization.

Positions in Pieris Pharmaceuticals Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 41 institutional holders increased their position in Pieris Pharmaceuticals Inc. [NASDAQ:PIRS] by around 8,974,782 shares. Additionally, 38 investors decreased positions by around 3,696,640 shares, while 19 investors held positions by with 19,255,569 shares. The mentioned changes placed institutional holdings at 31,926,991 shares, according to the latest SEC report filing. PIRS stock had 24 new institutional investments in for a total of 6,467,709 shares, while 21 institutional investors sold positions of 1,662,175 shares during the same period.